Comparison of Efficacy of Daily Sofosbuvir and Declatasvir with Alternate Day Sofosbuvir and Declatasvir in Hepatitis C Patients on Hemodialysis in Pakistani Population

Objective: compare the efficacy of daily Sofosbuvir plus Declatasvir with alternate day and in HCV patients on hemodialysis. Study design: Randomized clinical trial Place duration: department general medicine Nishtar hospital, Multan from March 2020 to 2021 one year duration. Methodology: A total 260 were enrolled study divided into two groups (1 2) by convenient sampling technique. Non probability consecutive technique was used. Group 1 treated group 2 Declatasvir. SPSS version 23.1 used for data entry analysis. Results: The liver enzymes hematological parameter noted after 24th weeks. mean differences at baseline weeks within statistically significant, (p<0.001). Viral load detectable, RVR, ETR, SVR 24 91.5% vs 88.5%, 98.5% 97.7% 90.8% respectively. Conclusion: In Pakistani population hepatitis C virus is endemic like some other countries. hemodialysis daclatasvir safe effective greater as days even genotype 3. Keywords: Sofosbuvir, Daclatasvir, HCV, Hemodialysis, Genotype 1,2,3